The global burn care market is anticipated to grow at a considerable CAGR of 7.4% during the forecast period (2024-2031). Thermal burns are skin injuries caused by excessive heat, typically from contact with hot surfaces, hot liquids, steam, or flame. Thermal burn incidents hold the higher percentages propelling the burn care market. According to the National Institutes of Health (NIH), approximately 450,000 patients receive treatment for burns annually, and about 30,000 require admission to burn centers. Thermal burns account for 86.0% of these cases, of which 43.0% result from fire/flame, 34.0% from scalds, and 9.0% from contact with hot objects. Additionally, 4.0% involve electrical burns, 3.0% chemical burns, and the remaining 7.0% are categorized as other types of burns. Approximately 6.5% of all burned patients receive treatment in specialized burn centers. Burns occurring in the home account for 25.0% of all serious burns. Annually, approximately 3,400 patients casualties from burns or related complications such as smoke inhalation, carbon monoxide or cyanide poisoning, organ failure, or infection. Roughly 72.0% of these fatalities occur from residential fires.
Browse the full report description of “Burn Care Market Size, Share & Trends Analysis Report by Product (Foam Dressing, Collagen Dressing, Hydrogel Dressing, Hydrocolloid Dressing, Alginate Dressing, Wound Contact Layers, Film Dressing, and Others), by Depth of Wound (Full Thickness Burns, Partial Thickness Burns, and Minor Burns), and by End-User (Hospitals, Outpatient Facilities, Home Care, and Others), Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/burn-care-market
Such factors compelled the manufacturers to introduce the product to meet the growing demand. Hence, in September 2023, Vericel Corp., a pioneer in advanced therapies for sports medicine and severe burn care markets, revealed the commercial availability of NexoBrid® (anacaulase-bcdb) in the US for the removal of eschar in adults with deep partial or full-thickness thermal burns. NexoBrid (anacaulase-BCDB) is a botanical drug product featuring proteolytic enzymes and is specifically indicated for individuals with deep partial- and/or full-thickness thermal burns. Further, Food and Drug Administration (FDA) approval significantly boosts the burn care market by implanting confidence, expanding adoption, and attracting investment, contributing to market growth. In June 2021, Mallinckrodt plc, a biopharmaceutical company, received approval from the US FDA for StrataGraft®. This product consists of allogeneic cultured keratinocytes and dermal fibroblasts embedded in murine collagen. It is indicated for the treatment of adults with thermal burns that contain complete dermal elements, demanding clinical surgical intervention for deep partial-thickness burns.
Market Coverage
• The market number available for – 2023-2031
• Base year- 2023
• Forecast period- 2024-2031
• Segment Covered-
o By Product
o By Depth of Wound
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes 3M Co., Cardinal Health, Inc., Johnson & Johnson Services, Inc., Smith & Nephew Plc, and others.
Key questions addressed by the report
Global Burn Care Market Report Segment
By Product
By Depth of Wound
By End-User
Global Burn Care Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/burn-care-market